Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesGoodwill & IntangiblesIntangiblesLiabilities and Shareholders EquityMinority InterestNon-Current AssetsNon-Current Deferred Tax LiabilityOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Retained EarningsShareholder's EquityShares OutstandingShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Barinthus Biotherapeutics (BRNS) Liabilities and Shareholders Equity (2020 - 2025)

Barinthus Biotherapeutics (BRNS) has disclosed Liabilities and Shareholders Equity for 6 consecutive years, with $129.6 million as the latest value for Q2 2025.

  • For the quarter ending Q2 2025, Liabilities and Shareholders Equity fell 30.62% year-over-year to $129.6 million, compared with a TTM value of $271.6 million through Sep 2025, down 65.6%, and an annual FY2023 reading of $214.5 million, down 20.61% over the prior year.
  • Liabilities and Shareholders Equity was $129.6 million for Q2 2025 at Barinthus Biotherapeutics, down from $142.0 million in the prior quarter.
  • Across five years, Liabilities and Shareholders Equity topped out at $286.1 million in Q1 2022 and bottomed at $129.6 million in Q2 2025.
  • Average Liabilities and Shareholders Equity over 5 years is $228.2 million, with a median of $246.1 million recorded in 2023.
  • The sharpest move saw Liabilities and Shareholders Equity soared 454.05% in 2021, then crashed 30.62% in 2025.
  • Year by year, Liabilities and Shareholders Equity stood at $280.7 million in 2021, then fell by 3.74% to $270.2 million in 2022, then fell by 20.61% to $214.5 million in 2023, then dropped by 12.04% to $188.7 million in 2024, then tumbled by 31.34% to $129.6 million in 2025.
  • Business Quant data shows Liabilities and Shareholders Equity for BRNS at $129.6 million in Q2 2025, $142.0 million in Q1 2025, and $188.7 million in Q3 2024.